Sagili KD, Satyanarayana S, Chadha SS, Wilson NC, Kumar AMV, et al.
2018-02-01 • Global Health Action
2018-02-01 • Global Health Action
BACKGROUND:
The Global Fund encourages operational research (OR) in all its grants; however very few reports describe this aspect. In India, Project Axshya was supported by a Global...
Chavan VV, Dalal A, Nagaraja SB, Thekkur P, Mansoor H, et al.
2020-06-16 • PLOS One
2020-06-16 • PLOS One
Background
Imipenem, an intravenous antibiotic is recommended for use in drug resistant tuberculosis (DR-TB) when an effective regimen with combination of other second line drugs is...
Tripathi U, Nagaraja SB, Tripathy JP, Sahu S, Parmar M, et al.
2015-03-21 • Public Health Action
2015-03-21 • Public Health Action
SETTING All multidrug-resistant tuberculosis (MDR-TB) patients who had completed 6 months of treatment under the Revised National Tuberculosis Control Programme (RNTCP) in Uttar Prad...
Diabetes mellitus (DM) and smoking are risk factors for adverse outcomes in the treatment of tuberculosis (TB). In a tertiary care hospital at Belgaum in the South Indian State of Karnat...
